Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Oncolys BioPharma Inc. (4588.T)
Tokyo, JP
Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the United States. Its robust pipeline features Telomelysin (OBP-301), an oncolytic adenovirus, currently in Phase II clinical trials for the treatment of gastric, gastroesophageal junction, head and neck, and esophageal cancers, and in Phase I trials for hepatocellular carcinoma. Other key developments include OBP-702, a telomerase-specific oncolytic adenovirus in preclinical stages for solid tumors; OBP-2011, also preclinical, targeting SARS-CoV-2 infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed Phase IIb clinical trials for HIV; and OBP-801, a histone deacetylase inhibitor, which is in Phase I clinical trials for solid tumors and preclinical assessment for ophthalmic applications. Additionally, the company is advancing TelomeScan (OBP-401 and OBP-1101), a cancer detection drug designed to identify living circulating tumor cells in cancer patients' blood. Oncolys BioPharma also offers diagnostic medications and inspection services. The company boasts various licensing and collaborative agreements with institutions such as Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Founded in 2004, Oncolys BioPharma Inc. is based in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.31% | +5.67% | +16.91% | +33.39% | +207.14% | +95.72% | +444.51% | +382.51% | +143.46% | +252.29% | -17.17% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-9.0%
-
EPS growth Biotechnology: +29.7%-3.7% Q1'26: +56.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-7,070.8% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-7,177.1% Q1'26: -13,615.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-342.4% Q1'26: -215.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+17.8% Q1'26: +17.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.16× Q1'26: -0.43× (vs Q1'25)
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
121.30M
est: 120.00M (+1.1%)
|
178.31M
est: 80.00M (+122.9%)
|
229.14M
est: 200.00M (+14.6%)
|
168.55M
est: 230.00M (-26.7%)
|
1.30B
est: 1.20B (+8.7%)
|
314.18M
est: 300.00M (+4.7%)
|
642.49M
est: 400.00M (+60.6%)
|
976.18M
est: 1.00B (-2.4%)
|
63.04M
est: 300.00M (-79.0%)
|
31.38M
est: 1.00B (-96.9%)
|
28.55M
est: 300.00M (-90.5%)
|
| EBITDA |
-833.34M
est: -120.00M (-594.4%)
|
-909.40M
est: -80.00M (-1,036.8%)
|
-1.08B
est: -200.00M (-441.2%)
|
-1.23B
est: -230.00M (-432.7%)
|
-901.54M
est: -1.20B (+24.9%)
|
-2.08B
est: -300.00M (-594.1%)
|
-1.60B
est: -400.00M (-300.3%)
|
-1.14B
est: -1.00B (-14.1%)
|
-1.93B
est: -300.00M (-543.2%)
|
-1.68B
est: -1.00B (-67.6%)
|
-2.05B
est: -300.00M (-582.8%)
|
| EBIT |
-850.46M
est: -120.00M (-608.7%)
|
-925.12M
est: -80.00M (-1,056.4%)
|
-1.08B
est: -200.00M (-442.0%)
|
-1.23B
est: -230.00M (-433.6%)
|
-904.65M
est: -1.20B (+24.6%)
|
-2.09B
est: -300.00M (-595.7%)
|
-1.61B
est: -400.00M (-301.9%)
|
-1.14B
est: -1.00B (-14.2%)
|
-1.93B
est: -300.00M (-544.0%)
|
-1.68B
est: -1.00B (-67.6%)
|
-2.05B
est: -300.00M (-582.9%)
|
| Net Income |
-857.29M
est: -2.31B (+62.8%)
|
-931.40M
est: -2.37B (+60.7%)
|
-1.09B
est: -3.03B (+64.0%)
|
-1.23B
est: -2.58B (+52.3%)
|
-912.35M
est: -633.11M (-44.1%)
|
-2.10B
est: -1.82B (-15.1%)
|
-1.62B
est: -2.46B (+34.4%)
|
-1.15B
est: -2.02B (+43.0%)
|
-1.94B
est: -1.64B (-18.4%)
|
-1.68B
est: -594.26M (-183.5%)
|
-2.06B
|
| SGA |
503.00M
est: 1.64B (-69.4%)
|
663.02M
est: 1.10B (-39.5%)
|
599.12M
est: 2.74B (-78.1%)
|
625.40M
est: 3.15B (-80.2%)
|
1.07B
est: 16.45B (-93.5%)
|
877.98M
est: 4.11B (-78.6%)
|
725.94M
est: 5.48B (-86.8%)
|
574.64M
est: 13.71B (-95.8%)
|
583.10M
est: 4.11B (-85.8%)
|
1.72B
est: 17.23B (-90.0%)
|
582.00M
est: 5.17B (-88.7%)
|
| EPS |
-93.35
est: -105.60 (+11.6%)
|
-101.18
est: -108.60 (+6.8%)
|
-106.23
est: -138.60 (+23.4%)
|
-104.55
est: -118.40 (+11.7%)
|
-65.55
est: -29.00 (-126.0%)
|
-145.58
est: -83.40 (-74.6%)
|
-95.50
est: -112.80 (+15.3%)
|
-66.31
est: -92.30 (+28.2%)
|
-108.92
est: -75.00 (-45.2%)
|
-77.17
est: -23.10 (-234.1%)
|
-80.00
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Magnus Jaderberg | Chief Medical Officer of Oncolys USA Inc. | — | — |
| Talia Biran | President Oncolys USA Inc. | — | female |
| Yasunari Kashihara | MD of Business Development & Risk Management and Director | — | male |
| Yasuo Urata | Chairman, Chief Executive Officer & President | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4588.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
